{
    "2020-11-13": [
        [
            {
                "time": "2023-10-18",
                "original_text": "New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender",
                "features": {
                    "keywords": [
                        "Novartis",
                        "inclisiran",
                        "LDL-C reduction",
                        "month 17",
                        "effective",
                        "sustained"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}